On January 12th, 2018, the CRCHUM Conferences invites Theo Van der Kwast, Professor and Consultant Urogenital Pathology, Director of Research – Laboratory Medicine Program, Toronto. During this conference, he will try to connect traditional pathology with modern genetic findings in prostate cancer.
Prostate cancer is a common malignancy in older men with highly variable clinical behavior varying from indolent to metastatic. Histopathological grading remains the strongest prognosticator and is the mainstay of clinical decision-taking in men with prostate cancer diagnosis. The last decade has seen a rapid development of molecular-genetic techniques and prostate tissue-based genetic biomarker panels are now being marketed to improve prognostication. Intra-tumoral genomic heterogeneity may, however, impact their utility. Advancing recent insights in prostate cancer pathology led to the identification of a few architectural patterns with a strong prognostic impact. Deep sequencing of microdissected tumour samples enabled the generation of phylogenetic trees providing insights in the molecular-genetic evolution of prostate cancer. This lecture will try to connect traditional pathology with modern genetic findings in prostate cancer.
Guest of the 2018 Institut du Cancer de Montréal Scientific Day
This conference will be presented in English.
Friday, January 12th, 2018, at Noon.
Auditorium of the CRCHUM, R05.210 and R05.220
900 Saint-Denis Street, 5th floor
Montreal (Quebec) H2X 0A9
Theo Van der Kwast, MD, PhD, FRCPC
Professor and Consultant Urogenital Pathology,
Director of Research – Laboratory Medicine Program, Toronto
About CRCHUM Conferences
The CRCHUM Conferences are free weekly meetings featuring renowned scientific speakers from various disciplines. These conferences are accredited by the Royal College of Physicians and Surgeons of Canada as continuing professional development activities. The CRCHUM conferences are made possible thanks to the financial support of our partners: AstraZeneca, Banque Nationale, Biron, Charles River, GSK Canada, Lilly, Médicaments novateurs Canada, Merck, Pfizer, Québecor, Roche & Servier.